Menu Search
Equities

Novo Nordisk A/S

NOVO B:CPH

Novo Nordisk A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (DKK)738.60
  • Today's Change-8.20 / -1.10%
  • Shares traded1.50m
  • 1 Year change+50.95%
  • Beta0.8502
Data delayed at least 15 minutes, as of May 25 2022 15:59 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Financials data is unavailable for this security.

Inc stmt in DKKIncome statement in DKKView more

Year on year Novo Nordisk A/S grew net income 13.33% from 42.14bn to 47.76bn primarily through revenue growth (126.95bn to 140.80bn). For while the costs associated with cost of goods, selling, general and administrative and debt all increased as a percentage of sales, the 10.91% growth in revenues contributed enough to still see net income improve.
Gross margin83.38%
Net profit margin33.11%
Operating margin42.15%
Return on assets29.15%
Return on equity78.92%
Return on investment57.87%
More ▼

Cash flow in DKKView more

In 2021, cash reserves at Novo Nordisk A/S fell by 1.51bn. However, the company earned 55.00bn from its operations for a Cash Flow Margin of 39.06%. In addition the company used 31.61bn on investing activities and also paid 25.49bn in financing cash flows.
Cash flow per share23.86
Price/Cash flow per share23.43
Book value per share29.24
Tangible book value per share10.20
More ▼

Balance sheet in DKKView more

Novo Nordisk A/S has a Debt to Total Capital ratio of 27.69%, a higher figure than the previous year's 4.84%.
Current ratio0.9052
Quick ratio0.693
Total debt/total equity0.3829
Total debt/total capital0.2769
More ▼

Growth rates in DKK

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 14.29% and 15.15%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked the highest relative to its industry peers.
Div yield(5 year avg)2.16%
Div growth rate (5 year)6.47%
Payout ratio (TTM)36.62%
EPS growth(5 years)6.74
EPS (TTM) vs
TTM 1 year ago		16.48
More ▼
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.